Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-11-18

Clinical Trial Update: Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates the safety and tolerability of escalating intravenous doses of PF-05231023 in adults with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PF-05231023

Snippet

Sponsor: Pfizer | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED | Results posted: 2016-11-18